LOCATION & TRAVEL
The meeting will be held at the Fairmont Hotel MacDonald (10065 100 St., Edmonton, AB). A special rate of $229.00 for a standard guest room (Fairmont Room: single/double occupancy) is available for conference delegates. To avoid disappointment, book by calling toll-free: 1.800.257.7544 or Local: +1.780.424.5181, please specify that you are booking under the Garrod Symposium 2018 room block to receive these reduced rates.

REGISTRATION
ONLINE: The quickest, most secure method is registering online. Registration is available for Visa/MasterCard holders at the meeting organizer’s website: www.interprofessional.ubc.ca/initiatives/garrodsymposium2018

BY FAX: Fax your completed registration form to: 1-604-822-4835


MAIL: Send the registration form with cheque to this address:

IN 9580 REGISTRATION, Interprofessional Continuing Education, The University of British Columbia, Room 105-2194 Health Sciences Mall, Vancouver, BC, V6T 1Z3, Canada

Participants paying by credit card outside of North America: Please inform your credit card company of the transaction as some banks put a block on credit card payments made outside your country.

TUITION FEES & MEETING PROGRAM
Please see the registration form (last page) for details. The tuition fee includes: welcome reception (May 10), breakfast (May 11 & 12), lunch (May 11 & 12), webinars and workshops (May 10-12), Garrod Association membership rate (if selected) and a certificate of attendance. Registration for the dinner event on Friday will also be available at an extra cost. Pre-registration before/on April 6, 2018 is strongly recommended to take advantage of the early-bird rate. To qualify for the Garrod Association member’s rate, one must pay the fee for membership dues during the registration process.

We will be including presenter slides (if the presenter permits) in our meeting program. We will send this program to you electronically (for free) a few days prior to the meeting but if you wish to purchase the paper copy that will be distributed on-site, please select the $20 option on the registration page.

CANCELLATION & REFUND POLICY
Notifications of cancellations must be sent by email to registration.ipce@ubc.ca on or before April 6, 2018 in order for registration fees to be refunded. If you have been invoiced but not paid the fees, you are still liable to pay the cancellation charges below:

• Up to and including April 6, 2018: Registration fee will be refunded less 20% cancellation fee.
• After April 6 2018: No refunds on registration fees will be made. Substitutions can be made.

CREDITS
This conference has been approved by the Canadian Association of Genetic Counsellors (CAGC) for 12.58 CECs. For additional information and updates regarding credits, please refer to the symposium organizer’s website: www.interprofessional.ubc.ca.

CONTACT
For additional enquiries, please contact Jo at 604-822-0054 or jo.ipce@ubc.ca.
The Garrod Association and the Program Committee gratefully acknowledge the generous contributions and financial support from the following organizations:

**PLATINUM**

- Alexion
- Biogen
- Shire
- Horizon Therapeutics
- Amicus Therapeutics

**GOLD**

- Sanofi
- Genzyme
- Recordati Rare Diseases Canada
- Pfizer

- Working together for a healthier world
- pfizer.ca

**BRONZE**

- Actelion
- PerkinElmer
- Vitacca
- Medunik Canada
**Advances in Laboratory Diagnosis of Lysosomal Storage Disorders**

*Tim Wood, PhD, FACMG, Director, Metabolic Laboratory, Greenwood Genetic Center, Greenwood, SC, USA*

1. Comprehend the general process of enzymatic assays commonly used for the diagnosis of LSDs
2. Recognize the limitations of urinary screening assays particularly for the MPS disorders
3. Compare an enzyme-first testing strategy with the classic screening strategies for identifying patients with a lysosomal storage disorder
4. Integrate molecular testing into testing for LSDs
5. Assess how novel urinary testing methods can improve/enhance treatment monitoring

**Dietary Management in MMA, PA and MSUD: Focus on Transplantation**

*Gregory Enns, MB, ChB, Director, Biochemical Genetics Program, Department of Pediatrics, Stanford University, Stanford, CA, USA*

1. Discuss perioperative nutrition in liver transplantation for patients with MMA, PA, and MSUD
2. Describe natural and metabolic protein tolerance pre vs post-transplant in MMA, PA, and MSUD

The session will conclude with discussion of three case studies to highlight nutritional aspects of liver transplantation in inherited metabolic disorders.
Program Friday

May 11, 2018

7:00-8:00  Registration Open & Breakfast (Provided)  
(Room: Jasper Room & Drawing Room)

8:00-9:30  Plenary Session II:  
Liver Transplant  
(Room: Empire Ballroom)

Liver Transplantation: The Modern Era  
Patricia Kawada, Clinical Lecturer, Department of Pediatrics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB

1. Review Indications for liver transplantation  
2. Current liver transplantation listing and allocation in Canada  
3. Surgical anatomy of liver transplantation  
4. Outcomes of liver transplantation

Transplants in Patients with Inborn Errors of Metabolism  
Aneal Khan, MD, MSc, FRCP, FCCMG, Associate Professor, Department of Medical Genetics and Paediatrics, Alberta Children's Hospital Research Institute, Cumming School of Medicine, University of Calgary, Metabolic Diseases Clinic, Calgary, AB

1. Understanding diverse use of transplants in patients with inborn errors of metabolism  
2. Understanding that there are continuous medical issues that need to be monitored after transplant  
3. To anticipate future challenges in transplant

Discussion

9:30-10:00  Refreshment Break & Exhibitors & Posters  
(Mezzanine Level)

10:00-11:50  Plenary Session III:  
Liver Transplant in Urea Cycle Disorders  
(Room: Empire Ballroom)

Liver transplant experience for Urea Cycle disorders in western Canada  
Alicia Chan, FRCP (C), FCCMG, Clinical Geneticist and Metabolics Specialist, Associate Professor, Edmonton Medical Genetics Clinic, University of Alberta, Edmonton, AB

1. Describe the experience of liver transplantation for Urea Cycle disorders in western Canada  
2. Describe the changes in liver transplantation for Urea Cycle disorders in western Canada from past to the present

The Toronto Experience in Liver Transplantation for Urea Cycle Disorders – Patient Selection and Outcome  
Yaron Avitzur, MD, Medical Director, Intestinal Rehabilitation and Transplantation, Gastroenterology, Hepatology and Nutrition; Director, Paediatric Gastroenterology Training Program, Gastroenterology, Hepatology and Nutrition; Staff Gastroenterologist, Gastroenterology, Hepatology and Nutrition, The Hospital for Sick Children; Associate Professor, Department of Paediatrics, Faculty of Medicine, University of Toronto, Toronto, ON

1. Describe the experience of liver transplantation for UCDs in Toronto  
2. Describe the changes in liver transplantation for UCDs including patient selection and post-transplant outcomes

Cognitive Outcomes in Liver Transplant  
Shailly Jain, MD, FRCP, FCCMG, Clinical Geneticist & Metabolics Specialist, Associate Professor, Edmonton Medical Genetics Clinic, University of Alberta, Edmonton, AB

1. Describe the cognitive outcomes in pediatric patients following liver transplant.  
2. Compare and contrast these outcomes when transplant is done due to an inborn error of metabolism.

Discussion

11:50-12:30  Lunch (provided)  
(Room: Jasper Room & Drawing Room)

12:30-13:00  Dessert & Exhibits (provided)  
(Mezzanine Level)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Description</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00-14:30</td>
<td><strong>Plenary Session IV: Liver Transplant for Organic Acid Disorders</strong>&lt;br&gt;(Room: Empire Ballroom)</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Liver Transplantation for Organic Acidemias</strong>&lt;br&gt;&lt;br&gt;Gregory Enns, MB, ChB, Director, Biochemical Genetics Program, Department of Pediatrics, Stanford University, Stanford, CA</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1. List possible indications for liver transplantation in patient who have organic acidemias&lt;br&gt;2. Summarize potential risks and benefits of liver transplantation for organic acidemias&lt;br&gt;3. Discuss outcome data related to survival and neurological status post-transplantation</td>
<td></td>
</tr>
<tr>
<td>14:30-15:00</td>
<td><strong>Discussion</strong></td>
<td></td>
</tr>
<tr>
<td>15:00-16:30</td>
<td><strong>Plenary Session V: Liver Transplant for MSUD and Tyrosinemia</strong>&lt;br&gt;(Room: Empire Ballroom)</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Liver Transplant for Maple Syrup Urine Disease</strong>&lt;br&gt; Komudi Siriwardena, MBChB (Otago), FRACP, FCCMG, Clinical Geneticist and Metabolics Specialist, Associate Professor, Edmonton Medical Genetics Clinic, University of Alberta, Edmonton, AB</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1. Summarize current trends for liver transplantation in MSUD&lt;br&gt;2. Discuss the benefits of transplantation in MSUD</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Tyrosinemia: Current situation and challenges</strong>&lt;br&gt;Fernando Alvarez, MD, Director, Liver Transplant Program, CHU Sainte-Justine; Professor, Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Faculty of Medicine, University of Montreal, Montreal QC</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1. Update challenges in the diagnosis of tyrosinemia&lt;br&gt;2. Summarize current results on the treatment of tyrosinemia&lt;br&gt;3. Discuss the indications and outcome of liver transplantation in Type I Tyrosinemia</td>
<td></td>
</tr>
<tr>
<td>16:30-17:45</td>
<td><strong>Discussion</strong></td>
<td></td>
</tr>
<tr>
<td>19:00-23:00</td>
<td><strong>Garrod Symposium Gala Dinner</strong>&lt;br&gt;Pioneer Award Presentation and Entertainment&lt;br&gt;(Location: Muttart Conservatory)&lt;br&gt;Transportation will be provided.</td>
<td></td>
</tr>
</tbody>
</table>
Plenary Session VI: Cardiomyopathies and metabolic disorders
(Room: Empire Ballroom)

Pediatric Cardiomyopathies and Cardiac Transplantation in Metabolic Disorders
Jennifer Conway, MD, Assistant Professor, Division of Pediatric Cardiology, Department of Pediatrics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB

1. Understand the impact of metabolic diseases on the heart in children
2. Discuss the outcomes of children with cardiac involvement
3. Discuss the role of advanced heart failure therapies in the management of children with metabolic conditions

Cardiomyopathies in Adults
Gavin Oudit, MD, PhD, FRCP, Director, Heart Failure Program, Canada Research Chair in Heart Failure; Clinician-Scientist, Mazankowski Alberta Heart Institute; Associate Professor, Department of Medicine, University of Alberta, Edmonton, AB

1. Describe the causes of cardiomyopathies in adults
2. Explain the pathophysiology of cardiomyopathies
3. Discuss the management of adult patients with cardiomyopathies: role of genome editing and precision medicine

Mitochondrial respiratory chain disorders Cardiomyopathy
Komudi Siriwardena, MBChB (Otago), FRACP, FCCMG, Clinical Geneticist and Metabolics Specialist, Associate Professor, Edmonton Medical Genetics Clinic, University of Alberta, Edmonton, AB

1. Explain common respiratory chain disorders associated with high risk of cardiomyopathy.
2. Discuss Cardiac transplantation for respiratory chain disorders in the literature.

Discussion
Executive Committee

Pierre Allard, PhD, CSPQ, FCCMG
Clinical Chemist, Sainte-Justine University Health Center
Montreal, QC

Pranesh Chakraborty
MD, FRCPC, FCCMG
Associate Professor, Pediatrics and Biochemistry/Microbiology/Immunology, University of Ottawa; Medical Director, Newborn Screening Ontario; Metabolic Physician, Department of Pediatrics, Children's Hospital of Eastern Ontario, Ottawa, ON

Jo Nam
Senior Education Manager
Interprofessional Continuing Education
The University of British Columbia, Vancouver, BC

Andreas Schulze, MD, PhD, FRCPC
Professor Paediatrics and Biochemistry
University of Toronto, Toronto, ON

Local Programming and Organizing Committee

Shailly Jain, MD, FRCPC, FCCMG (Chair)
Clinical Geneticist and Metabolics Specialist
Associate Professor
Edmonton Medical Genetics Clinic
University of Alberta, Edmonton, AB

Alicia K.J. Chan, MD, FRCP (C), FCCMG
Clinical Geneticist/Associate Professor
Edmonton Medical Genetics Clinic,
University of Alberta, Edmonton, AB

Komudi Siriwardena
MBChB (Otago), FRACP, FCCMG,
Clinical Geneticist and Metabolics Specialist,
Associate Professor,
Edmonton Medical Genetics Clinic,
University of Alberta, Edmonton, AB

Angela Schinkinger
Genetic Counsellor
Edmonton Medical Genetics Clinic
University of Alberta, Edmonton, AB

Clara Hung, RN, BScN
Edmonton Medical Genetics Clinic
Stollery Children's Hospital, Edmonton, AB

Iveta Sosova
Biochemical Geneticist, Genetic Laboratory Services, Alberta Health Services; Joint Laboratory Head, Newborn Metabolic Screening and Biochemical Genetics Laboratory; Assistant Professor, Dept of Lab Medicine and Pathology, University of Alberta, Edmonton, AB

Sydney St. James
Metabolic Dietitian
Edmonton Medical Genetics Clinic
Stollery Children's Hospital, Edmonton, AB
1. A case series study to optimize the hemodialysis prescription for the treatment of hyperammonemic patients with ornithine transcarbamylase deficiency
   Chong C\textsuperscript{1,2}, Wade A\textsuperscript{2,3}, Khan A\textsuperscript{2,3}
   \textsuperscript{1}Faculty of Science, University of Calgary, Calgary, AB, \textsuperscript{2}Alberta Children’s Hospital Research Institute, Calgary, AB, \textsuperscript{3}Faculty of Medicine, University of Calgary, Calgary, AB

2. Urea cycle disorders: Is fibrosis a common feature in all subtypes? A close look at liver cell injury from a Western Canadian Liver Transplantation Center
   Jain-Ghai S\textsuperscript{1}, Chan A\textsuperscript{1}, Siriwardena K\textsuperscript{1}, Khan A\textsuperscript{4}, Yap J\textsuperscript{1}, Sergi C\textsuperscript{3}
   \textsuperscript{1}Department of Medical Genetics, University of Alberta and Stollery Children’s Hospital, Edmonton, AB \textsuperscript{2}Department of Pediatrics, University of Alberta and Stollery Children’s Hospital, Edmonton, AB, \textsuperscript{3}Department of Lab Medicine and Pathology, University of Alberta and Stollery Children’s Hospital, Edmonton, AB, \textsuperscript{4}Medical Genetics and Pediatrics, University of Calgary, Alberta Children’s Hospital, Calgary, AB

3. An innovative treatment trial of peroxisomal biogenesis disorders with anti-pexophagy agents
   Sondheimer N\textsuperscript{1,3}, Kim P\textsuperscript{2}
   \textsuperscript{1}The Division of Clinical and Metabolic Genetics, The Hospital for Sick Children, Toronto, ON, \textsuperscript{2}Program in Cell Biology, The Hospital for Sick Children, Toronto, ON, \textsuperscript{3}Program in Genetics and Genome Biology, The Hospital for Sick Children, Toronto, ON

4. Kidney disease and organ transplantation in methylmalonic acidemia
   Prasad C\textsuperscript{2}, Noone D\textsuperscript{1}, Riedl M\textsuperscript{1}, Ratko S\textsuperscript{2}, Avitzur Y\textsuperscript{3}, Sharma A\textsuperscript{2}, Filler G\textsuperscript{2}, Siriwardena K\textsuperscript{4}
   \textsuperscript{1}Division of Nephrology, The Hospital for Sick Children, Toronto, ON, \textsuperscript{2}Department of Paediatrics, Western University, London, ON, \textsuperscript{3}Division of Hepatology and Gastroenterology, Department of Paediatrics, University of Toronto, Toronto, ON, \textsuperscript{4}Department of Medical Genetics University of Alberta/Stollery Children’s Hospital, Edmonton, AB

5. Characteristics of a Canadian cohort of children with inherited metabolic diseases for which liver transplantation is a therapeutic option: Chart-reported findings from the Canadian Inherited Metabolic Diseases Research Network
   Chakraborty P\textsuperscript{1,2}, Pugliese M\textsuperscript{3}, Tingley K\textsuperscript{2}, Kowalski M\textsuperscript{4}, Lamoureux M\textsuperscript{1}, Potter B\textsuperscript{5}, Coyle D\textsuperscript{3}, Wilson K\textsuperscript{6}, Brunel C\textsuperscript{4}, Buhas D\textsuperscript{3}, Chapman M\textsuperscript{7}, Chan A\textsuperscript{8}, Dyack S\textsuperscript{6}, Feigenbaum A\textsuperscript{7}, Geraghty M\textsuperscript{7}, Giezen A\textsuperscript{10}, Gillis J\textsuperscript{9}, Goebie S\textsuperscript{9}, Karp N\textsuperscript{11}, Kozenko M\textsuperscript{12}, Kronick J\textsuperscript{8}, Langley E\textsuperscript{9}, Little J\textsuperscript{3}, Mackenzie J\textsuperscript{2,3}, Maranda B\textsuperscript{14}, Mhanni A\textsuperscript{15}, Mitchell G\textsuperscript{4}, Mitchell J\textsuperscript{4}, Nagy L\textsuperscript{9}, Pender A\textsuperscript{12}, Potter M\textsuperscript{2}, Prasad C\textsuperscript{3}, Ratko S\textsuperscript{7}, Salvarinova R\textsuperscript{9}, Schulze A\textsuperscript{8}, Siriwardena K\textsuperscript{4}, Sondheimer N\textsuperscript{6}, Sparkes R\textsuperscript{16}, Stockler S\textsuperscript{9}, Trakadis Y\textsuperscript{5}, Turner L\textsuperscript{17}, Ueda K\textsuperscript{9}, Van Karnebeek C\textsuperscript{10}, Vallance H\textsuperscript{10}, Vandersteen A\textsuperscript{5}, Walia J\textsuperscript{13}, Wilson B\textsuperscript{5}, Yuskiv N\textsuperscript{10}, Jain S\textsuperscript{7}
   \textsuperscript{1}Newborn Screening Ontario, Children’s Hospital of Eastern Ontario, Ottawa, ON \textsuperscript{2}Department of Pediatrics, University of Ottawa, Ottawa, ON, \textsuperscript{3}School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON, \textsuperscript{4}CHU Ste-Justine, Montréal, QC, \textsuperscript{5}Montreal Children’s Hospital, Montréal, QC, \textsuperscript{6}Dalhousie University, Halifax, NS, \textsuperscript{7}University of Alberta, Edmonton, AB, \textsuperscript{8}University of Toronto/Hospital for Sick Children, Toronto, ON, \textsuperscript{9}Children’s Hospital of Eastern Ontario, Ottawa, ON, \textsuperscript{10}BC Children’s Hospital, Vancouver, BC, \textsuperscript{11}Western University, London, ON, \textsuperscript{12}McMaster University, Hamilton, ON, Canada, \textsuperscript{13}Queen’s University, Kingston, ON, Canada, \textsuperscript{14}University of Sherbrooke, Sherbrooke, QC, \textsuperscript{15}University of Manitoba, Winnipeg, MB, \textsuperscript{16}Alberta Children’s Hospital, Calgary, AB, \textsuperscript{17}Memorial University, St. John’s, NL
1. Controversies of jump analysis: squat jump is the optimal technique for use in clinical environments
   Bieber J, Sidhu K, Robu I, Ursulak G, Ramage B, Khan A

2. Transient Plasma Methionine, Total Homocysteine, S-adenosylmethionine and S-adenosylhomocysteine elevations in a patient diagnosed with NGly1 deficiency; a Congenital Disorder of Deglycosylation
   Chang C, Martin S, Sinasac D, Al-Hertani W

3. Improving health care delivery for children diagnosed with rare metabolic diseases by learning from families and providers: protocol for phase I, a prospective cohort study of families’ health care experiences

4. Carnitine uptake defect due to a 5’UTR mutation
   Geraghty M, Bulman D, Faghfoury H, Tein I, Hartley T, Verbeeten K

5. Case Report: Two siblings with type VII 3-methylglutaconic aciduria due to mutations in CLPB gene

6. MITO-FIND: Mitochondrial Functional and Integrative Next Generation Diagnostics
   Kerr M, Hume, Sabouny R, Shutt T, Khan A

7. Plasma derived cell-free mitochondrial DNA (cf-mtDNA): A novel and non-invasive method to sequence intact mtDNA
   Khan A, Newell C, Hume S, Greenway S, Shearer J, Podemski L

8. Anesthetic Complications in patients with Niemann Pick C: Is there a higher risk?
   Khan A, Beckie T

9. Screening for Fabry cardiomyopathy using cardiac magnetic resonance imaging
   Koo D, Kerr M, White J, Khan A

10. Idiopathic chylous ascites in an adult patient with LRPPRC-associated Leigh syndrome: a coincidence or a rare clinical manifestation of mitochondrial dysfunction?
    Levtoya A, Mitchell G, Giraldeau M, Daoust L, Fenyes D

11. Expanding the Clinical Phenotype of NUS1-CDG, a rare Congenital Disorder of Glycosylation?
    McPherson M, Sargeant L, He M, Al-Hertani W

12. Diagnostic challenges in a patient with global developmental delay, lipodystrophy, periventricular leukomalacia and spasticity
    McPherson M, Innes M, Sargeant L, He M, Al-Hertani W

13. Review of C5OH as a newborn screening target

14. Targeted Reduction in Pathogenic Heteroplasmy Through Binding of G-Quadruplex DNA
    Naeem M, Maheshan R, Costford S, Sondheimer N

15. Drug Approval System in Canada
    Omar F, Koo D, Khan A

16. Liver transplantation for inborn errors of metabolism: A survey of care practices and delivery in Canadian metabolic clinics

17. D-2-hydroxyglutaric aciduria in a patient with speech delay due to a novel homozygous deletion in the D2HGDH gene
    Phillips E, Sasarman F, Sinasac D, Al-Hertani W

18. Experiences with health care for children with inherited metabolic diseases in Canada: Updated findings from a multi-centre survey

19. Establishing core outcome sets for phenylketonuria (PKU) and medium-chain Acyl-CoA dehydrogenase (MCAD) deficiency in children: rapid review findings

20. Characterization of ocular changes in Gaucher disease: Case Report
21. Combined therapy trial of L-carnitine supplementation and L-valine restriction in a patient with 3-Hydroxyisobutyric aciduria due to a novel homozygous missense variant in the HIBADH gene
Sasarman F, Rombough C, Reeves M, Fung E, Sinasac D, Al-Hertani W

22. The unexpected diagnosis: Case report of an atypical presentation of pyruvate dehydrogenase deficiency in an adult male
Schinkinger A, Hung C, Shyu W, Siriwardena K

23. Medial rectus muscle and orbitofrontal region SUV measurements: a novel approach to detecting hypometabolism in mitochondrial disease (MD)
Shanoada R, Molnar C, Khan A

24. Investigating in vivo bone architecture in hypophosphatasia using high-resolution peripheral computed tomography
Sidhu K, Boyd S, Khan A

25. Importance of diet in treatment of mitochondrial respiratory chain disorders (RCDs)
Siriwardena K, Ashkin A, Schinkinger A, Hung C, Shyu W, Sheehan M, St James S

26. Evolution of GFM1 gene phenotype with age
Siriwardena K, Jain S, Hung C, Chan A

27. Impaired mitochondrial fatty acid oxidation due to synergistic heterozygosity for ACADM/ETFA alleles in a child with Rett syndrome
Sosova I, Waters P, Goez H, Sinasac D, Sasarman, Ridsdale R, Cyr D, Jain-Ghai S

28. Utility of whey protein powder to establish dietary protein tolerance in young children with phenylketonuria
Sparkes R, Rombough C

29. Suboptimal metabolic control following liver transplantation in a young adult with maple syrup urine disease
Sparkes R, Reeves M, Strauss K, Carson V

30. Case report: Improved creatine kinase with decreased simple and supplemental carbohydrate intake in two siblings with Glycogen Storage Disease type IIIa
St. James S, Chan A

31. HSD10 disease and p.Leu122Val variant: mild clinical phenotype and probable founder effect in French-Canadian patients from Quebec

32. Analysis of glutaric acid, 3-hydroxyglutaric acid and glutaryl carnitine in dried urine spots by liquid chromatography tandem mass spectrometry as possible biomarkers of catabolism in glutaric aciduria type 1
Yu A, Geraghty M, Al-Dirbashi O
# The Garrod Symposium 2018 Registration Form

**AFFILIATION / PROFESSION**  
(please select only one)  
- Physician  
- Registered Nurse  
- Dietician  
- Genetic Counsellor  
- Lab  
- Other: ____________________________

**DELEGATE INFORMATION**  
Please write in block letters and use one registration form per person. Please photocopy the form if needed.  
- Dr.  
- Mr.  
- Ms.  

<table>
<thead>
<tr>
<th>Last Name</th>
<th>First Name</th>
<th>Initials</th>
</tr>
</thead>
</table>

Institution / Organization  
Mailing Address  
City  
Prov/State  
Postal Code  
Daytime Telephone Number / Local  
Email Address for Meeting Correspondence  
(If applicable) Please inform us of any dietary requirements for the meeting: ____________________________

**REGISTRATION RATES**  
(Rates include all applicable taxes)  

<table>
<thead>
<tr>
<th></th>
<th>On or before April 6, 2018</th>
<th>After April 6* or Onsite</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-Members</td>
<td>$450</td>
<td>$550</td>
</tr>
<tr>
<td>Members**</td>
<td>$330</td>
<td>$430</td>
</tr>
</tbody>
</table>
| **(This rate includes the $30 Garrod Association membership dues)**  
Student/Trainee | $100                        | $150                     |
| Allied Health Professional | $100                       | $150                     |

**SOCIAL EVENTS**  
*Additional Guest for Welcome Reception (Thursday)*  
Gala Dinner at Muttart Conservatory - Friday  
Regular Garrod Attendee | $80  
Additional guest(s) | $120  
TOTAL: ____________________________

**METHOD OF PAYMENT**  

**Payment by Credit Card** Most secure and easy method  
1. Complete the full registration online at [www.interprofessional.ubc.ca](http://www.interprofessional.ubc.ca) with your Visa or MasterCard.  
2. Fax* the registration form to +1-604-822-4835 and indicate that you would like to pay with Visa or MasterCard. We will send you the secure online link to enter your credit card information.  
*Please do not fax your credit card information  

**Payment by Cheque**  
Please make your cheque payable to the University of British Columbia and send it along with this form to: Interprofessional Continuing Education, The University of British Columbia, Room 105-2194 Health Sciences Mall, Vancouver, BC V6T 1Z3.

**Alternative Payment Methods**  
Mail or fax complete registration form along with one of the following:  
1. Signed purchase order (PO)  
2. Letter of Authorization (LOA) from the manager on the organization’s letterhead stating that they will be paying the registration fees. Must include the amount of registration fees, name and contact information of the manager  
3. Signed cheque requisition form (ChReq)  

Please indicate below how you would like to pay:  
- □ Cheque: Payment is enclosed with mailed registration form  
- □ Credit Card: Please email me a secure link to enter my credit card number  
- □ PO/LOA/ChReq: Purchase order/letter of authorization/cheque requisition form is enclosed with faxed/mailed registration form